In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Dicerna Pharma (NASDAQ: DRNA). The company’s shares opened today at $17, close to its 52-week high of $17.50.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 33.0% and a 56.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dicerna Pharma with a $18.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.50 and a one-year low of $3.15. Currently, Dicerna Pharma has an average volume of 477.4K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DRNA in relation to earlier this year. Last month, James Weissman, the CBO of DRNA bought 14,680 shares for a total of $50,206.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.
